BALAXI PHARMACEUTICALS LIMITED

400 billion

rgeted Expansion Product Sourcing Regions .. Existing/targeted markets have aggregate GDP of$ 400 billion and pharma imports of$ 6 billion Existing/targeted markets have aggregate GDP of $ 400 billion and

6 billion

Regions .. Existing/targeted markets have aggregate GDP of$ 400 billion and pharma imports of$ 6 billion Existing/targeted markets have aggregate GDP of $ 400 billion and pharma imports of $ 6 billion 9

INR 49.36 crore

entral African Republic Successfully completed fund raising exercise through Preferential issue – INR 49.36 crore Capex plans – Project initiated for our first Pharma ' ' ' ' ' Formulation manufacturing facilit

25%

ver, in our strategic focused market of LATAM, by continuing our core competencies, revenue grew by 25% and it has contributed more than 50% of pharma revenue with a healthy gross profit margin of 39%.

50%

of LATAM, by continuing our core competencies, revenue grew by 25% and it has contributed more than 50% of pharma revenue with a healthy gross profit margin of 39%. During the quarter, we received 25 ne

39%

by 25% and it has contributed more than 50% of pharma revenue with a healthy gross profit margin of 39%. During the quarter, we received 25 new product registrations. As on 30 June, the number of regist

38.9%

eptional Item * Earnings Per Share (INR) EBITDA EBITDA Margin % PAT PAT Margin % 65.96 25.64 38.9% 7.83 11.87% 5.32 8.06% (46.67) 3 (38.84) (58.9%) (41.34) (62.7%) 82.78 34.52 41.7% 17.0

11.87%

* Earnings Per Share (INR) EBITDA EBITDA Margin % PAT PAT Margin % 65.96 25.64 38.9% 7.83 11.87% 5.32 8.06% (46.67) 3 (38.84) (58.9%) (41.34) (62.7%) 82.78 34.52 41.7% 17.03 20.6% 14.1

8.06%

r Share (INR) EBITDA EBITDA Margin % PAT PAT Margin % 65.96 25.64 38.9% 7.83 11.87% 5.32 8.06% (46.67) 3 (38.84) (58.9%) (41.34) (62.7%) 82.78 34.52 41.7% 17.03 20.6% 14.15 17.1% - 14

58.9%

DA Margin % PAT PAT Margin % 65.96 25.64 38.9% 7.83 11.87% 5.32 8.06% (46.67) 3 (38.84) (58.9%) (41.34) (62.7%) 82.78 34.52 41.7% 17.03 20.6% 14.15 17.1% - 14.15 17.03 20.6% 14.15 1

62.7%

PAT Margin % 65.96 25.64 38.9% 7.83 11.87% 5.32 8.06% (46.67) 3 (38.84) (58.9%) (41.34) (62.7%) 82.78 34.52 41.7% 17.03 20.6% 14.15 17.1% - 14.15 17.03 20.6% 14.15 17.1% YoY (20.3%)

41.7%

5.64 38.9% 7.83 11.87% 5.32 8.06% (46.67) 3 (38.84) (58.9%) (41.34) (62.7%) 82.78 34.52 41.7% 17.03 20.6% 14.15 17.1% - 14.15 17.03 20.6% 14.15 17.1% YoY (20.3%) (25.7%) (280 bps)

“Over the medium term, Balaxi sees several new market opportunities opening up for its product lines.”

“With the increase in the number of product offerings, we expect to further increase our market share in the countries of our focus.”

“We also plan to launch our operations in new countries in these regions.”

Expansion initiated

1

Expansion initiated

Nicaragua, Ecuador, Chile (Latin America) Products Vast range of essential OTC medicines – with healthy mix of generics and branded generics 833 product registrations in six countries 700 registrations submitted or in the pipeline Supply Chain Outsourced production from WHO GMP certified plants in India, China and Portugal Distribution Deep presence through 38 warehouses and on-ground fleet support Transformation Balaxi New initiatives strengthening functionality in supply chain, regulatory affairs and customer service Establishing the Company’s first pharmaceutical formulation facility in Hyderabad Successful process being replicated in other frontier markets; expansion plans in other global markets over near to medium term Centralized digital procurement, regulatory management and customized CRM tools ' ' ' ' ' ········r - 5 _j _______ _ I I I I I I I Key Success Factors Market Selection Methodology  Focus on countries with high-potential economic growth framework  Identify non-Eng